home / stock / allk / allk news

ALLK News and Press, Allakos Inc. From 02/11/19

Stock Information
Company Name: Allakos Inc.
Stock Symbol: ALLK
Market: NASDAQ
Website: allakos.com
Menu
ALLK ALLK Quote ALLK Short ALLK News ALLK Articles ALLK Message Board
Get ALLK Alerts

News, Short Squeeze, Breakout and More Instantly...
ALLK - Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts

-- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients -- -- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by HSS7 in Xolair Naïve CSU patients -- -- 54% (7/13) complete itch response by ISS7 in Xolair Naïve...
ALLK - Allakos to Host Investor Day on February 19 in New York City

REDWOOD CITY, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced that it will host an Investor Day on February 19 th starting at 12:00 pm ET in New Y...

ALLK - "Positive" AK002 data fails to lift Allakos; shares down 11% premarket

Thinly traded Allakos (NASDAQ: ALLK ) slumps  11%  premarket on light volume on the heels of new data from a Phase 2 clinical trial evaluating lead drug AK002 in patients with urticaria (hives). More news on: Allakos, Healthcare stocks news, Stocks on the move, Read more .....

ALLK - Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism

-- 82% (9 of 11) response rate in patients with cholinergic urticaria -- -- 70% (7 of 10) response rate in patients with symptomatic dermographism -- REDWOOD CITY, Calif., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the t...
Previous 10 Next 10